Detailed Information on Publication Record

DASTYCH, Milan, Libuse HUSOVA, Kvetoslava AIGLOVA, Tomas FEJFAR and Milan DASTYCH. Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. ABINGDON: INFORMA HEALTHCARE, 2021, vol. 81, No 2, p. 116-120. ISSN 0036-5513. Available from: https://dx.doi.org/10.1080/00365513.2020.1864835.

Other formats: BibTeX LaTeX RIS

TY  - JOUR
ID  - 1773327
AU  - Dastych, Milan - Husova, Libuse - Aiglova, Kvetoslava - Fejfar, Tomas - Dastych, Milan
PY  - 2021
TI  - Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis
JF  - SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
VL  - 81
IS  - 2
SP  - 116-120
EP  - 116-120
PB  - INFORMA HEALTHCARE
SN  - 00365513
KW  - Manganese
KW  - copper
KW  - cholestasis
KW  - primary biliary cirrhosis
KW  - primary sclerosing cholangitis
UR  - https://www.tandfonline.com/doi/full/10.1080/00365513.2020.1864835
N2  - The liver and the biliary tree form the main excretory route of manganese (Mn) and copper (Cu). Cholestasis, can lead to the accumulation of these trace elements in the organism, resulting in toxicity to the basal ganglia of the central nervous system. The aim of our study was to reveal the influence of long-term cholestasis on the Mn and Cu levels in the blood of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). We recruited patients with PBC (n = 20) and PSC (n = 32). A control group (n = 40) was also set up. We also examined serum bile acid concentrations and liver enzyme activities. We did not observe any significant differences in any of these parameters between the PBC and PSC groups. The Mn and Cu levels in the PBC and PSC patients differed significantly from the that in the control group (p < 0.0001 and p < .021, respectively). Patients in whom the laboratory cholestasis markers normalized during ursodeoxycholic acid treatment (18/52;35%) presented with significantly lower levels of Mn and Cu (p = .015 and p = .012, respectively). Ten PSC patients showed normal levels of Mn and Cu six months after liver transplantation. Fine tremors, rigidity, dysarthria, and hypomimia were reported in nine (23%), eight (20%), four (10%), and eight (20%) patients, respectively. In addition to monitoring the cholestasis levels, liver function, and Mn and Cu levels during the long-term treatment of PBC and PSC patients, it is important to also regularly monitor the occurrence and development of extrapyramidal symptoms of Parkinson's-like syndromes.
ER  -

Basic information
Original name	Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis
Authors	DASTYCH, Milan (203 Czech Republic, guarantor), Libuse HUSOVA (203 Czech Republic), Kvetoslava AIGLOVA (203 Czech Republic), Tomas FEJFAR (203 Czech Republic) and Milan DASTYCH (203 Czech Republic, belonging to the institution).
Edition	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, ABINGDON, INFORMA HEALTHCARE, 2021, 0036-5513.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30219 Gastroenterology and hepatology
Country of publisher	United Kingdom of Great Britain and Northern Ireland
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 2.209
RIV identification code	RIV/00216224:14110/21:00121702
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.1080/00365513.2020.1864835
UT WoS	000607121500001
Keywords in English	Manganese; copper; cholestasis; primary biliary cirrhosis; primary sclerosing cholangitis
Tags	14110213, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/6/2021 08:06.

Abstract
The liver and the biliary tree form the main excretory route of manganese (Mn) and copper (Cu). Cholestasis, can lead to the accumulation of these trace elements in the organism, resulting in toxicity to the basal ganglia of the central nervous system. The aim of our study was to reveal the influence of long-term cholestasis on the Mn and Cu levels in the blood of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). We recruited patients with PBC (n = 20) and PSC (n = 32). A control group (n = 40) was also set up. We also examined serum bile acid concentrations and liver enzyme activities. We did not observe any significant differences in any of these parameters between the PBC and PSC groups. The Mn and Cu levels in the PBC and PSC patients differed significantly from the that in the control group (p < 0.0001 and p < .021, respectively). Patients in whom the laboratory cholestasis markers normalized during ursodeoxycholic acid treatment (18/52;35%) presented with significantly lower levels of Mn and Cu (p = .015 and p = .012, respectively). Ten PSC patients showed normal levels of Mn and Cu six months after liver transplantation. Fine tremors, rigidity, dysarthria, and hypomimia were reported in nine (23%), eight (20%), four (10%), and eight (20%) patients, respectively. In addition to monitoring the cholestasis levels, liver function, and Mn and Cu levels during the long-term treatment of PBC and PSC patients, it is important to also regularly monitor the occurrence and development of extrapyramidal symptoms of Parkinson's-like syndromes.

Abstract

The liver and the biliary tree form the main excretory route of manganese (Mn) and copper (Cu). Cholestasis, can lead to the accumulation of these trace elements in the organism, resulting in toxicity to the basal ganglia of the central nervous system. The aim of our study was to reveal the influence of long-term cholestasis on the Mn and Cu levels in the blood of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). We recruited patients with PBC (n = 20) and PSC (n = 32). A control group (n = 40) was also set up. We also examined serum bile acid concentrations and liver enzyme activities. We did not observe any significant differences in any of these parameters between the PBC and PSC groups. The Mn and Cu levels in the PBC and PSC patients differed significantly from the that in the control group (p < 0.0001 and p < .021, respectively). Patients in whom the laboratory cholestasis markers normalized during ursodeoxycholic acid treatment (18/52;35%) presented with significantly lower levels of Mn and Cu (p = .015 and p = .012, respectively). Ten PSC patients showed normal levels of Mn and Cu six months after liver transplantation. Fine tremors, rigidity, dysarthria, and hypomimia were reported in nine (23%), eight (20%), four (10%), and eight (20%) patients, respectively. In addition to monitoring the cholestasis levels, liver function, and Mn and Cu levels during the long-term treatment of PBC and PSC patients, it is important to also regularly monitor the occurrence and development of extrapyramidal symptoms of Parkinson's-like syndromes.